Antagonizing interleukin-21 receptor activity

Details Antagonizing interleukin-21 receptor activity Antagonizing interleukin-21 receptor activity

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 38/17 (2006.01) A61P 37/00 (2006.01) C07K 19/00 (2006.01) C12N 5/10 (2006.01) C12N 15/63 (2006.01)

Patent

CA 2574848

Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor ("IL-21R" or "MU- 1"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo,e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).

L'invention concerne des procédés et des compositions permettant d'inhiber l'activité du récepteur (MU-1) d'interleukine 21 (IL-21)/IL-21 au moyen d'antagonistes de IL-21 ou du récepteur de IL-21 ("IL-21R" ou "MU-1"). Des antagonistes de IL-21/IL-21R peuvent être utilisés pour induire la suppression immunitaire in vivo, par exemple pour le traitement, l'amélioration ou la prévention de troubles auto-immunes ou inflammatoires, notamment par exemple une maladie intestinale inflammatoire (IBD), la polyarthrite rhumatoïde (RA), le rejet de transplantation/greffe, le psoriasis, l'asthme, la fibrose et le lupus érythémateux disséminé (SLE).

Affiliated with

Also associated with

Rating

Antagonizing interleukin-21 receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonizing interleukin-21 receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonizing interleukin-21 receptor activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1702996